Key result
Only 41% (95% CI 37-45) of medical directors at U.S. opioid treatment programs were aware of methadone's QT-prolonging properties, and just 24% were aware of its association with torsade de pointes.
Population
692 physicians licensed as medical directors for accredited U.S. opioid treatment programs in 2006
Design
Cross-sectional
Authors
Loading...
Low awareness of methadone's QT risks among OTP directors may warrant targeted education; leaves open effects on prescribing or arrhythmia outcomes.
Cross-Sectional (n=692)
Yes
A national survey revealed that a majority of opioid treatment program physicians are unaware of methadone's QT-prolonging properties and its association with torsade de pointes.
Krantz et al. (2007) conducted a cross-sectional in Opioid dependence treatment (n=692). Survey of physician awareness was evaluated on Knowledge of methadone's QT-prolonging effects (95% CI 37-45). Only 41% (95% CI 37-45) of medical directors at U.S. opioid treatment programs were aware of methadone's QT-prolonging properties, and just 24% were aware of its association with torsade de pointes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: